Praxis and Relmada target depression as Athira and Taurx tackle Alzheimer’s.
Praxis, Proqr and Nordic Nanovector are awaiting important data.
The group gets a long-awaited win in kidney disease, but sales potential is hard to call.
Second-quarter deal values plummeted as Covid-19 spread and the prices of target companies spiralled.
Aduro finally runs up the white flag on Sting agonism, and becomes a listed shell for Chinook Therapeutics.